88.73
-1.65%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About iRhythm Holdings,
From its filings with the US Securities and Exchange Commission
iRhythm Holdings, is based in San Francisco, California. Its shares trade on Nasdaq under the ticker IRTC. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $747.1m and a net loss of $44.6m. At that date it held total assets of $1.02bn and shareholders' equity of $152.7m. By business, Contracted third-party payors brought in 52.5% of revenue, followed by Centers for Medicare and Medicaid at 24.0% and Healthcare institutions at 16.8%.
Each iRhythm product offering combines a wire-free, patch-based, 14-day wearable biosensor (United States Food and Drug Administration (“FDA”)-cleared, Conformité Européenne (“CE”)-marked and Japan Pharmaceuticals and Medical Devices Agency ("PMDA")-approved, as applicable) that continuously records electrocardiogram ("ECG") data with a proprietary cloud-based data analytic software (also FDA-cleared, CE-marked and Japan PMDA-approved, as applicable) (such biosensor and software together, an "iRhythm ACM System") to help physicians monitor patients and diagnose arrhythmias.
Since first receiving clearance from FDA for our technology in 2009, we have supported physician and patient use of this technology and provided ambulatory cardiac monitoring ("ACM") services from our Medicare-enrolled independent diagnostic testing facilities (“IDTFs”) with our qualified technicians. We have provided ambulatory cardiac monitoring services, including long-term continuous monitoring (“LTCM”) services ("LTCM Services"), short-term continuous monitoring, and mobile cardiac telemetry (“MCT”) monitoring services ("MCT Services" and collectively, the “iRhythm Services”), using the iRhythm ACM System. LTCM services and MCT Services are medical procedures typically ordered by physicians for patients not suspected of having life-threatening arrhythmias, but who are suspected of having infrequent, difficult-to-detect, or asymptomatic arrhythmias.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 20 Oct 2016
- Employees
- 2,400
- Website
- irhythmtech.com ↗
- Head office
- 699 8TH STREET, San Francisco, CA, 94103
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Abhijit TalwalkarIndependent Chairman of the Board$272,207
- Mr. Quentin BlackfordPresident, Chief Executive Officer, Director, since 2021$9.3m
- Mr. Daniel WilsonChief Financial Officer$2.5m
- Dr. Minang TurakhiaExecutive Vice President - Product Innovation Officer, Chief Scientific Officer, Chief Medical Officer$3.3m
- Ms. Sumi ShrishrimalExecutive Vice President, Chief Risk Officer
- Mr. Mervin SmithExecutive Vice President - Business Operations
- Mr. Patrick MurphyChief Business Officer, Chief Legal Officer$3.0m
- Mr. Chad PattersonChief Commercial Officer$3.6m
- Mr. Bruce BodakenIndependent Director$227,707
- Ms. Karen LingIndependent Director$224,707
- Ms. Karen McginnisIndependent Director
- Dr. Cathleen Noel MerzIndependent Director$217,207
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 58
- Social
- 49
- Governance
- 56
- Direct emissions (scope 1)
- 67.07 t
- Energy emissions (scope 2)
- 541.03 t
- Women in the workforce
- 60.5%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- iRhythm Technologies Inc is known for its innovative and advanced medical technology. The company's wearable devices and digital health solutions enable efficient monitoring and analysis of cardiac rhythms, providing accurate and reliable results.
- iRhythm Technologies Inc holds a strong market position in the cardiac monitoring industry. Its products have been widely adopted by healthcare professionals and institutions, and the company continues to grow its customer base.
- iRhythm Technologies Inc is renowned for its high customer satisfaction levels. Its user-friendly devices, timely support, and detailed analysis reports contribute to the positive experience of healthcare providers and patients.
- The company has established strategic partnerships with key players in the healthcare sector, allowing it to expand its reach and collaborate on research and development efforts.
Weaknesses
- iRhythm Technologies Inc heavily depends on its cardiac monitoring product line for revenue generation. This overreliance poses a potential weakness as a downturn in demand or technological advancements by competitors could impact the company's financial stability.
- Although iRhythm Technologies Inc has achieved success domestically, its international presence remains limited. Expanding into global markets may be challenging due to regulatory differences and competition.
Opportunities
- The rising adoption of telehealth and remote patient monitoring presents an opportunity for iRhythm Technologies Inc to expand its customer base. The company's advanced technology can address the growing need for remote monitoring solutions, especially in the post-pandemic healthcare landscape.
- iRhythm Technologies Inc could explore opportunities to expand into adjacent medical fields, such as respiratory or sleep disorders monitoring. Diversification of its product portfolio would help the company capture new market segments and increase its revenue streams.
Threats
- The cardiac monitoring industry is highly competitive, with established players and new entrants vying for market share. iRhythm Technologies Inc faces the constant threat of competitors offering similar or superior products, potentially impacting its market position.
- Compliance with regulatory requirements, both domestically and internationally, poses a threat to iRhythm Technologies Inc's operations. Changes in regulations or delays in obtaining necessary approvals could hinder the company's ability to launch new products or expand geographically.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.